AntiviralPK
Meeting category
Date(s)
11 Sep 2023 - 13 Sep 2023
Location
Rome, Italy
Meeting type
Hybrid Meeting

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2023

Related Enduring Materials

Enduring Materials
Virtual Program Book Antiviral PK 2023
Virtual Abstract Book Antiviral PK 2023

Day 1 - Monday, 11 September 2023

- 14:00
Opening Lecture: News in Antiviral Pharmacology: A Year in Review
Andrea Calcagno, MD, DTM&H
University of Torino, Italy
The Use of AI in Clinical Pharmacology
Session 1: Perspectives on the Role of ARV TDM in Clinical Pharmacology -
Is TDM Still Needed / Useful ?
Nancy Sheehan, PharmD, MSc
Université de Montréal and McGill University Health Centre, Canada
Minh Patrick Le, PharmD, PhD
University of Paris Cité, Bichat-Claude Bernard Hospital, France
Session 2: Special Topics in Clinical Pharmacology - Key Populations -
New(er) Antiretrovirals in Pregnancy and Breastfeeding
Catriona Waitt, MBChB, PhD
University of Liverpool, United Kingdom
Pharmacokinetics of Sofosbuvir-Based Direct Acting Antivirals for HCV in Pregnancy
Catherine Chappell, MD, MSc
University of Pittsburgh, United States
Abstract Oral Presentation #1: Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People with HIV
Mattia Berton
University Hospital Basel, Switzerland
Abstract Oral Presentation #2: Pharmacokinetic Data of Atazanavir/Ritonavir in Second-Line Treatment of Children Living with HIV: Results from the CHAPAS4-trial.
Anne Kamphuis
Radboud University Medical Center, The Netherlands

Day 2 - Tuesday, 12 September 2023

Session 3: Next-Generation Therapeutics – Long Acting Drugs -
Knowledge Gaps and Future Perspectives for Treatment Based on Long-Acting Technology
Andrew Owen, BSS, MSC, PhD, FSB
University of Liverpool, United Kingdom
A Year of CAB/RPV Use, What Have We Learned in the Real World
Emma Rubenstein, MD, MPH
Hôpital Saint-Louis, France
Abstract Oral Presentation #3: Preliminary Results of Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a Large National Cohort of People Living with HIV (ANRS-MIE-CARLA Study).
Caroline Solas Chesneau, PharmD, PhD
University Hospital of La Timone, Aix-Marseille University, France
Session 4: Abstract-Driven Session on Clinical Pharmacology on Pregnancy and HIV -
Abstract Oral Presentation #5: Intracellular Tenofovir-Diphosphate Concentrations with Tenofovir Alafenamide During Pregnancy and Postpartum in People with HIV: Results from IMPAACT 2026
Kristina Brooks, PharmD
University of Colorado Anschutz Medical Campus, United States
Abstract Oral Presentation #6: Temporal Changes in Dolutegravir and Raltegravir Glucuronide Metabolite to Parent Ratios during Pregnancy and Postpartum
Tim Cressey, MSc, PhD
Chiang Mai University, Thailand
Abstract Oral Presentation #7: Lower Exposure to Bictegravir in Third Trimester in Pregnant Women Living with HIV
Lena Van Der Wekken
Radboudumc, The Netherlands
Abstract Oral Presentation #8: Prediction of Maternal Pharmacokinetic of Bictegravir in Pregnancy Using Physiologically-Based Pharmacokinetic Modeling
Jeihun Kuack,
U.S. Food And Drug Administration, United States
Session 5: Challenges in Managing Complex Drug - Drug Interactions -
Management of Antiplatelet/DOAC DDIS (Pk/PD) - in Context of HIV, HCV, COVID Antiviral Therapy
Mike Emerson, PhD
Imperial College London, United Kingdom
Short Versus Extended Nirmatrelvir/R Treatment Course and Ensitrelvir: How Do DDIs Differ?
Catia Marzolini, PharmD, PhD
University Hospital of Basel, University Hospital of Lausanne, Switzerland; University of Liverpool, United Kingdom
Case Presentation - Complex DDI case
Dario Cattaneo, PharmD, PhD
Luigi Sacco University Hospital, Italy
Case Presentation - Complex DDI case
Giovanni Di Perri, MD, PhD
University of Turin, Italy
Session 6: Drug Interactions: PBPK Modelling and Pharmacodynamic Outcomes -
A (PK) Study in Scarlet: Investigating Target Concentrations​
Paolo Denti, PhD
University of Cape Town, South Africa
Abstract Oral Presentation #9: Physiologically Based Pharmacokinetic Modeling of Lenacapavir Pharmacokinetics and Model Validation with Drug-Drug Interactions Between Lenacapavir with Voriconazole or Rifampicin
Naveed Shaik
Gilead Sciences, Inc., United States
Abstract Oral Presentation #10: Dolutegravir But not Bictegravir Exposure Increases in Vitro Platelet Aggregation
Renos Keniyopoullos
Imperial College London, United Kingdom
Abstract Oral Presentation #11: Genetic Variants Influencing Neuroinflammation Biomarkers in Different Clinical Groups of People Affected by HIV
Jessica Cusato
University of Turin, Department of Medical Sciences, Italy
Session 7: DDI Guidance: Regulatory Landscape and Challenges with Emerging/New Compounds -
Harmonization of DDI Guidelines Among Different Regulatory Agencies: Challenges and Opportunities
Elin Lindhagen, MSci Pharm, PhD
Swedish Medical Products Agency, Sweden
A Global Collaboration to Harmonize Guidelines for Clinical Management of Ritonavir-Boosted Nirmatrelvir DDIs
Alice K. Pau, PharmD, FIDSA
National Institute of Allergy and Infectious Disease, National Institutes of Health, United States
Abstract Oral Presentation #12: Nirmatrelvir/Ritonavir Real World Drug-Drug Interaction Management Experience.
Shahid Bukhari
Chelsea & Westminster Hospital, United Kingdom
Abstract Oral Presentation #13: A Retrospective Descriptive Study of the Management and Consequences of Drug-Drug Interactions between Nirmatrelvir/Ritonavir and Systemic Treatment for Cancer
Samantha Robertson
Kingston Health Sciences Centre, Canada
Abstract Oral Presentation #14: Management of Drug-Drug Interaction and Safety of Oral Anticoagulants with Nirmatrelvir-Ritonavir
Pierre Giguere
The Ottawa Hospital, Canada

Day 3 - Wednesday, 13 September 2023

Session 8: Pharmacologic Data on New and Pipeline Drugs - Industry Session -
Gilead Sciences
Ramesh Palaparthy, PhD
Gilead Sciences, United States
GSK - ViiV Healthcare
Jon Collins, PharmD
ViiV Healthcare, United States
Shionogi Inc.
Simon Portsmouth, MBChB, MD, FRCP
Shionogi Inc., United States
Atea Pharmaceuticals, Inc.
Xiao-Jian Zhou, PhD
Atea Pharmaceuticals, Inc., United States
Session 9: Abstract-Driven Session on Innovative Tools to Assess Drug Exposure and Adherence -
Abstract Oral Presentation #15: Adherence Blood Sampling Devices Are Not All Created Equal: A Comparative Investigation
Amanda Schauer
University of North Carolina-Chapel Hill, United States
Abstract Oral Presentation #16: PrEP at the Site-of-Action in Transgender Women: A Pharmacology Study of Blood and Rectal CD4+ T Lymphocytes
Mackenzie L. Cottrell, PharmD
University of North Carolina, Chapel Hill, United States
Abstract Oral Presentation #17: Saliva, Tear and Nasal PK of Ritonavir-boosted Nimatrelvir (Paxlovid) in Combination with Molnupiravir in Patients with Laboratory Confirmed COVID-19
Laura Dickinson, PhD
University of Liverpool, United Kingdom
Abstract Oral Presentation #18: A Novel Approach to Identify PK Determinants of Efficacy: Implications for HIV-1 Latency Reversal by Romidepsin
Lauren Tompkins
The University of North Carolina at Chapel Hill, United States
Charles Boucher Memorial Session: The Role of Tissue Pharmacology in Response and Cure -
Tissue-Specific Pharmacology: Knowledge and Knowledge Gaps
Charles Flexner, MD
Johns Hopkins University School of Medicine, United States
Tissue-Specific Pharmacology: How Clinically Important Is It
Saye Khoo, MD, PhD
Royal Liverpool University Hospital; University of Liverpool, United Kingdom